Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predictive Role of TP53, PIK3CA and MLL2 in ER+ HER2+ Breast Bancer: Biomarker Analysis of Neo-ALL-IN [NCT 01275859].

Anticancer research - 1 Oct 2020

Park Ji Hyun, Ahn Jin-Hee, Kim Jeong Eun, Jung Kyung Hae, Gong Gyungyub, Lee Hee Jin, Son Byung-Ho, Ahn Sei-Hyun, Kim Hak-Hee, Shin Hee Jung, Moon Dae-Hyuk, Kim Deokhoon, Kim Sung-Bae

Abstract excerpt

BACKGROUND/AIM: Somatic mutations were investigated in 21 patients with postmenopausal estrogen receptor (ER)-positive and human epidermal growth factor receptor-2 (HER-2)-positive (ER+HER2+) breast cancer (BC) treated with neoadjuvant letrozole and lapatinib, to identify their distinct molecular landscape. PATIENTS AND METHODS: We used tissue samples of 21 patients from phase II Neo ALL-IN cohort, and somatic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast
Share to Class I Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Estrogen Receptor alpha

Share to Lapatinib

Share to Neoplasm Proteins

Share to Progression-Free Survival

Share to Receptor, ErbB-2

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 32988919
DOI: 10.21873/anticanres.14608

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predictive Role of TP53, PIK3CA and MLL2 in ER+ HER2+ Breast Bancer: Biomarker Analysis of Neo-ALL-IN [NCT 01275859].PMID 32988919Read ↗

Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer.Semantic proximity Read ↗

Human Epidermal Growth Factor Receptor 2 Alterations and Prognostic Implications in All Subtypes of Breast Cancers.Semantic proximity Read ↗

Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial.Semantic proximity Read ↗

P53 immunohistochemistry is an ideal surrogate marker for TP53 mutation and a predictor of early metastasis in breast cancer: Real-world analysisSemantic proximity Read ↗

Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.Semantic proximity Read ↗

Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing.Semantic proximity Read ↗

Genomic alterations of ERBB receptors in cancer: clinical implicationsSemantic proximity Read ↗

Tumor Mutational Landscape and Its Correlation with Histopathological Characteristics in Breast CancerSemantic proximity Read ↗

Associations of HER2 Mutation With Immune-Related Features and Immunotherapy Outcomes in Solid Tumors.Semantic proximity Read ↗

Prognostic and predictive biomarkers with therapeutic targets in breast cancer: A 2022 update on current developments, evidence, and recommendationsSemantic proximity Read ↗

Somatic mutations in a multigene panel and impact on prognosis based on TP53 status in Chinese HER2-positive patients undergoing neoadjuvant therapy: A single-institution retrospective cohort.Semantic proximity Read ↗

Distinct clinicopathological characteristics, genomic alteration and prognosis in breast cancer with concurrent TP53 mutation and MYC amplification.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.